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 Abstract 
  Background:  The aim of this study was to explore the relationship between cerebrospinal fluid 
Alzheimer’s disease (AD) markers and depression in elderly people.   Method:   We included sub-
jects with AD as well as persons with subjective cognitive impairment and normal cognition. 
Depression was assessed with the Cornell Scale for Depression in Dementia, and a cut-off score 
of   1  6 was used to define depression. Cerebrospinal fluid was analyzed using commercially 
available assays for     -amyloid 1–42, total tau, and phosphorylated tau 181.   Results:   A total of 
183 participants (66.7% female) were included (92 with AD and 91 with subjective cognitive im-
pairment), with a mean age ( 8 SD) of 67.6  8  7.4 years, a Mini-Mental State Examination score of 
26.0   8   4.0, and a median Cornell Scale for Depression in Dementia score of 5 (range 0–19). De-
pression scores were not associated with higher phosphorylated tau 181 and total tau or re-
duced     -amyloid 1–42 in AD or non-demented subjects.   Conclusions:   These results suggest 
that AD pathology does not contribute to depression, indicating that other factors may be more 
important. Further studies of the aetiology of depression in elderly people with and without AD 
are warranted.    Copyright © 2012 S. Karger AG, Basel 
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 Introduction 
  Depression is one of the most common health problems in the elderly, and non-major 
depression syndromes such as minor depression occur in 4–13%, dysthymia in 2%, and clin-
ically significant symptoms of depression in 8–16% of patients, with major implications for 
quality of life, physical health, independent functioning, and costs   [1]  .
    There is a complex relationship between late-onset depression and cognitive impair-
ment. Executive dysfunction is common in depressed elderly subjects, and depression is 
more prevalent among patients with Alzheimer’s disease (AD) and other dementias than in 
non-demented elderly subjects; furthermore, there is emerging evidence that mid-life de-
pression is a risk factor for AD decades later  [2] . Finally, in many studies, depression has been 
found to be a prodromal syndrome of early AD   [2, 3]  .
    The aetiology of late-life depression is complex and only partially understood. Psycho-
social, genetic as well as brain changes probably contribute, and potential mechanisms in-
clude toxic stress, with the activation of the hypothalamic-pituitary-adrenal axis, hypercor-
tisolaemia, inflammation, and hippocampus atrophy, monoaminergic changes, and cerebro-
vascular disease   [4]  .
    There is evidence that AD pathology is a contributing factor to the development of de-
pression in elderly subjects with and without AD, possibly associated with decreased sero-
tonin, which is likely to be related to depression in AD   [5]   since serotonin influences the 
shifting in the processing of amyloid precursor protein towards amyloidogenic pathways   [6, 
7] . MRI studies have reported more hippocampal atrophy in elderly patients with depression 
  [8]  . Moreover, clinicopathological studies have reported more AD-type changes in AD pa-
tients with a previous history of depression compared to those without a history of depres-
sion   [9]  . The same authors also reported increased tangle pathology in AD patients with co-
morbid depression compared to those without depression   [10]  . Recent studies using amyloid 
PET imaging have, to some extent, been consistent with these autopsy findings  [11, 12] . How-
ever, autopsy studies of late-life depression without dementia have failed to find significant-
ly more AD pathology in depressed compared to non-depressed elderly persons   [13]  . Thus, 
the association between depression and AD pathology is not clear.
    In cerebrospinal fluid (CSF), a characteristic pattern of metabolites of amyloid plaques 
[low   -amyloid 1–42 (A  42)] and tau [increased total tau (t-tau) and phosphorylated tau 181 
(p-tau)] has been consistently shown in patients with AD   [14]  . However, the few studies that 
have explored whether AD-type changes in CSF are associated with depression have not 
found associations with more severe depression in mild AD   [15]   or elderly non-demented 
women   [16] .
    Taken together, there is inconsistent evidence regarding the role of AD-type pathologi-
cal changes in depression. Understanding the aetiology of depression in the elderly is impor-
tant for diagnostic purposes as well as background information for the development of nov-
el pharmacological strategies. We administered the Cornell Scale for Depression in Demen-
tia (CSDD)  [17]  to 183 elderly subjects who had been referred to a memory clinic and diagnosed 
as having AD or subjective cognitive impairment [SCI; i.e. normal cognitive functioning 
without a diagnosis of dementia or mild cognitive impairment (MCI)], and measured CSF 
levels of A  42, t-tau, and p-tau. The aim of this study was to test the hypothesis that AD-type 
changes, i.e. reduced A    42 and increased t-tau and p-tau, are associated with depression in 
elderly subjects with and without AD.50
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  M e t h o d s  
 Subjects 
  The base population for the study consisted of 1,154 referrals to the Memory Clinic at 
Karolinska University Hospital in Huddinge, Sweden, between 2007 and 2009. Inclusion cri-
teria for the current project were: (a) age 60 years or older, (b) CSDD administered, (c) lum-
bar puncture, and (d) diagnosis of AD or normal cognition (i.e. SCI). Excluded were patients 
with: (a) physical disease significantly affecting cognitive performance, (b) life-threatening 
disease with expected reduced survival time, (c) MCI, and (d) dementia due to diseases oth-
er than AD.
    All subjects signed informed consent prior to lumbar puncture, and the study was ap-
proved by the Ethical Committee at Karolinska University Hospital in Huddinge (43/03).
  A s s e s s m e n t  
  Participants underwent a medical examination and assessment of depression using the 
combined patient- and informant-based CSDD, which has excellent psychometric properties 
in both demented and non-demented people   [17, 18]  . For this study, a cut-off score of   1 6  was 
used to define depressed and non-depressed subjects, based on a validation study performed 
in Denmark   [19]  . The CSDD was completed by a licensed geriatrician or psychiatrist, or a re-
search nurse.
    For the dementia diagnosis, a standardized informant-based scale of the patients’ his-
tory of cognitive decline (Informant Questionnaire on Cognitive Decline in the Elderly)  [20]  
was administered, and dementia was staged using Global Deterioration Scales after a clinical 
medical examination including cognitive screening with the Mini-Mental State Examina-
tion (MMSE)  [21] . To aid in the diagnostic process, the majority of subjects completed a neu-
ropsychological examination: tests of verbal abilities (similarities and information), visuo-
spatial abilities (block design and Rey-Osterrieth copying), working memory (digit span and 
Corsi span), episodic memory (learning and retention after 30 min, Rey Auditory Learning 
Test), and executive functioning (Digit Symbol and Trail Making Test). Patients were diag-
nosed as having AD using ICD 10 criteria after a consensus meeting with clinicians and neu-
ropsychologists, taking into account all available information.
    In addition to the clinical assessment, brain imaging MRI or CT according to a demen-
tia protocol, routine blood tests, and CSF analyses were performed; furthermore, EEG was 
performed in a large subgroup.
  CSF  Measurement 
  CSF was obtained by lumbar puncture between the L3/L4 or L4/L5 intervertebral space 
using a 25-gauge needle and collected in 12-ml polypropylene tubes. Within 2 h, the CSF 
samples were centrifuged. A small amount of CSF was used for routine analysis, including 
total cells (leucocytes and erythrocytes), total protein, and glucose. CSF was aliquoted in 
polypropylene tubes of 0.5 or 1 ml and stored at –80    °    C until further analysis. CSF A   42,  t-
tau, and p-tau were measured by commercially available sandwich ELISAs (Innogenetics, 
Ghent, Belgium).
  S t a t i s t i c s  
 We divided the subjects into four groups based on the presence or absence of depression 
in AD and SCI. Group comparisons were made using parametric or non-parametric tests as 
appropriate. For the descriptive statistics presented in table 1 a 2 test and a pre-planned post 
hoc analysis have been used. The CSF values were compared using simple logistic regression 
comparing depressed and non-depressed subjects with and without AD in two separate anal-51
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yses.  In addition, Spearman’s correlation analyses were performed between the CSDD score 
and each of the three CSF measures in the total group and in the AD and SCI groups sepa-
rately. Ordered logistic regression was used to analyze the association between CSF measures 
and depression scores using the entire CSDD scale. Two models were used, adjusting for age 
and sex (Model 1) and age, sex, and MMSE score (Model 2).
  R e s u l t s  
  The sample included 183 patients. The characteristics of the four groups are shown in 
  table 1  . Age, MMSE score, and CSDD score, but not gender, differed significantly between 
the groups. The pre-planned post hoc analyses showed that in AD and SCI, the only signifi-
cant difference was in the non-demented group, with a lower age in the depressed compared 
to the non-depressed subjects (  table 1  ).
  CSF  Analyses 
  The median values of the three CSF measures in the four groups are shown in   table 2   
and   figures 1–3  . As expected, in the AD groups, t-tau and p-tau were higher and A   42  low-
Table 1. C  haracteristics of the study sample
All
(n = 183)
SCI A D
not 
depressed
(n = 51)
depressed
(n = 41)
p not  
depressed
(n = 60)
depressed
(n = 31)
p
Age, years 67.687.4 65.085.6 62.783.0 0.02 72.088.2 70.186.6 0.26
Females 122 (66.7) 32 (62.7) 32 (78.0) 0.11 38 (63.3) 20 (64.5) 0.9
Education, years 11.783.7 13.4 12.4 0.19 11.0 11.2 0.8
MMSE score 26.084.0 28.981.4 28.781.5 0.5 23.183.6 23.283.9 0.9
AD duration, years 3.282.3 3.0 3.2 0.6 3.0 3.4 0.5
CSDD score 5.0 (0–19) 3 (0–6) 11 (7–19) <0.0005 2 (0–6) 9 (7–14) <0.0005
Antidepressant use 61 (33.3) 10 (19.6) 12 (29.3) 0.28 26 (43.3) 13 (41–9) 0.9
Numbers represent mean 8 SD, n (%), or median (range).
Between-group comparisons were made using Mann-Whitney or 2 tests as appropriate.
Table 2.   CSF markers and depression in subjects with and without AD
SCI A D
not depressed
(n = 51)
depressed
(n = 41)
p* not depres  sed
(n = 60)
depressed
(n = 30)
p*
p-tau, pg/l 57.3 (31) 50.1 (23) 0.045 85.5 (42) 79.5 (31) 0.256
t-tau, pg/l 302 (157) 237 (145) 0.023 560.5 (496) 439 (240) 0.027
A42, pg/l 883 (372) 896 (298) 0.897 504 (160) 429 (154) 0.157
Num  bers represent median (interquartile range). 
* p values are based on logistic regressions with depressed/not depressed as outcome.52
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  Fig. 1–3.   Box plot of the three 
CSF markers in depressed and 
non-depressed patients with and 
without AD. 
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er than in the non-AD groups (all p values   !  0.001). T-tau differed significantly between AD 
patients with and without depression, with the depressed patients having lower values than 
the non-depressed AD patients, whereas p-tau and A    42 did not differ significantly. In the 
SCI group, both t-tau and p-tau were significantly lower in the depressed compared to the 
non-depressed group, whereas A    42 did not differ significantly.
  The correlation analyses were consistent with the above-mentioned findings. In the total 
group, bivariate correlations showed a significant negative correlation between the CSDD 
score and p-tau (Spearman’s      = –0.21, p = 0.004) as well as t-tau (     = –0.25, p = 0.001), but 
not with A    42 (p = 0.25). In the AD group, there was a trend towards a correlation between 
the CSDD score and t-tau (     = –0.21, p = 0.05), whereas no significant correlations between 
the CSDD score and CSF measures were found in the SCI group. The ordered regression 
analyses, adjusting for age and sex (Model 1) and for age, sex, and MMSE score (Model 2), 
showed similar findings (  table 3  ). Interpretations from Model 2 show that for each 10-pg/l 
increase in p-tau, the odds for having more depressive symptoms decreases by 8%, and for 
each 100-pg/l increase in t-tau, the odds for having more depressive symptoms decreases by 
15% (p = 0.008).
  Discussion 
 In this study, analysis of the three different CSF measures A  42, t-tau, and p-tau did not 
support the hypothesis that more severe AD pathologies such as amyloid plaques or tau pa-
thologies are associated with more severe depression. In contrast, depressed patients tended 
to have lower p-tau levels and, in particular, lower t-tau levels than those without depression, 
indicating less tau pathology and neurodegeneration. These findings were found both in pa-
tients with a clinical diagnosis of AD and in subjects without dementia, using either con-
tinuous data or categories based on cut-off scores for the CSDD and reference norms for CSF 
values, and also after adjusting for potential confounders.
  Few previous studies of CSF AD markers in patients with depression have been reported. 
One study reported on a population-based sample of 81 elderly women, 11 with major de-
pression   [16]  . They were without dementia up to 10 years after lumbar puncture. A   42  con-
centrations were higher among those with major depression compared to non-depressed 
women, whereas t-tau levels did not differ between the groups. p-tau was not measured in 
that study. In another study of patients with mild AD, apathy was associated with higher p-
tau levels, but no associations between CSF A    42, t-tau, or p-tau levels and the Neuropsy-
chiatric Inventory depression item were found  [15] . Thus, the current findings are consistent 
Table 3.   Associations between CSDD scores and CSF measures
Independent variable: p-tau/10 t-tau/100 A  42/100
OR p value OR p value OR  p value
Model 1 0.92 0.039 0.87 0.005 1.03 0.526
Model 2 0.92 0.071 0.85 0.008 0.98 0.811
Ord  ered regression analysis. Model 1: adjusting for age and sex. Model 2: adjusting for age, sex, and 
MMSE score.54
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with previous CSF studies suggesting that AD pathology does not contribute to depression 
in elderly subjects with or without AD.
  One previous clinicopathologic study reported more severe tau pathology in AD patients 
with comorbid depression compared to AD patients without depression   [10]  . Thus, it is pos-
sible that depression later in the disease course is more closely related to the underlying pa-
thology, whereas other factors are more important in the earlier stages. However, the effect 
of depression on neurofibrillary tangle occurrence was rather small, and the interval be-
tween depression diagnosis at study inclusion and death was nearly 10 years   [10]  . In another 
autopsy study, 10 patients with late-onset major depression were followed prospectively to 
death   [22]  . AD was the most frequent pathology, in particular among the 7 patients who de-
veloped dementia, but Lewy body pathology and stroke were also common. Although the 
study shows that AD and other pathologies probably contribute to dementia in patients with 
late-onset major depression, whether these pathologies are related to the symptoms of de-
pression was not reported. Finally, in a recent population-based clinicopathologic study of 
subjects who did not develop dementia during life, no association between AD-type chang-
es and depression could be observed   [13]  .
    Amyloid imaging provides another means of exploring the association between depres-
sion and AD pathology. In one such study, patients with remitted depression underwent de-
tailed neuropsychological assessment and Pittsburgh compound B (PiB) imaging   [11]  . Two 
subjects with normal cognition showed PiB retention in the normal range. In 3 of 6 patients 
with MCI, the PiB retention fell in the range of AD. However, associations between depres-
sion and PiB binding were not reported, and thus it is unclear whether the increased binding 
was related to cognitive impairment as a prodrome of AD or to the remitted depression   [11]  . 
In another PET study of non-demented subjects, a marker of amyloid plaques and neurofi-
brillary tangles was found to correlate with a self-report measure of depressive symptoms in 
both cognitively normal and MCI subjects   [12]  .
    Methodological limitations of the current study include the cross-sectional design; 
therefore, assumptions regarding causality cannot be made. The study sample was selected 
from referrals to a university memory clinic, and thus generalizations to the population are 
not possible. In particular, the non-AD group consisted of SCI subjects, with an increased 
proportion having an AD-type CSF profile   [23]  , and hence extrapolation to non-demented 
depressed elderly persons is difficult. The diagnosis of AD was clinical, and thus there is a 
possibility of misdiagnosis. However, the lack of association between AD markers and de-
pression was independent of AD diagnosis; therefore, inaccurate diagnosis is an unlikely 
explanation.
  Conclusion 
 Our CSF analyses did not support the hypothesis that depression is associated with more 
AD pathology, neither in subjects with AD nor in subjects without AD, suggesting that oth-
er factors are more important contributors to depression in the elderly. Future studies should 
explore the role of potential aetiological factors for depression in the elderly, such as neuro-
inflammation and cerebrovascular disease as well as psychosocial factors.55
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